Kenvue Inc. (NYSE:KVUE) Position Boosted by Isthmus Partners LLC

Isthmus Partners LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 550,504 shares of the company’s stock after purchasing an additional 14,964 shares during the period. Isthmus Partners LLC’s holdings in Kenvue were worth $12,733,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in KVUE. Advisors Asset Management Inc. bought a new stake in shares of Kenvue in the 1st quarter valued at approximately $206,000. Janus Henderson Group PLC grew its stake in shares of Kenvue by 53.7% in the 1st quarter. Janus Henderson Group PLC now owns 165,162 shares of the company’s stock valued at $3,541,000 after buying an additional 57,679 shares in the last quarter. Tidal Investments LLC grew its stake in shares of Kenvue by 47.5% in the 1st quarter. Tidal Investments LLC now owns 131,764 shares of the company’s stock valued at $2,828,000 after buying an additional 42,418 shares in the last quarter. LRI Investments LLC bought a new stake in shares of Kenvue in the 1st quarter valued at approximately $106,000. Finally, Swedbank AB bought a new stake in shares of Kenvue in the 1st quarter valued at approximately $27,856,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent research reports. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research note on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft boosted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. UBS Group boosted their target price on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, Piper Sandler boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $24.13 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market cap of $46.26 billion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. The business has a fifty day moving average of $22.92 and a 200-day moving average of $20.96.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.31 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.40%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.